News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 06 - 30

Monthly Health Watch | June 2026

On June 10, 2026, the "Shenzhen Yifeng Mingyuan Seed Venture Investment Partnership (Limited Partnership)," established with equity participation from the Shenzhen Science and Technology Innovation Seed Fund, officially completed its business registration. This marks a critical step forward in Yifeng Capital's strategic deployment in ultra-early-stage investments.Notably, this month has brought a steady stream of positive developments across Yifeng Capital's portfolio ecosystem, with multiple investee companies achieving breakthrough progress in financing rounds and core busi...

浏览次数：18

查看详情>>

发布时间: 2026 - 06 - 25

Efung News | HighLight Pharma’s JAK1/TYK2 Inhibitor Proposed for Breakthrough Therapy Designation in

June 24, 2026 – HighLight Pharma's JAK1/TYK2 inhibitor TLL-018 has been proposed for inclusion in the Breakthrough Therapy Designation (BTD) program for the treatment of rheumatoid arthritis.Founded in 2017, HighLight Pharma focuses on developing innovative therapies for autoimmune and inflammatory diseases. Its lead asset, TLL-018, is a highly selective JAK1/TYK2 inhibitor. The drug is currently undergoing two pivotal Phase III registrational trials for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA), both of which have met their primary endpoints. The company is also ex...

浏览次数：10

查看详情>>

发布时间: 2026 - 06 - 24

Efung News | The First and Only One in China! RuiJing Bio’s NGS-Based Thyroid Cancer Molecular Detec

On June 23, 2026, Shanghai RuiJing Biotechnology Co., Ltd. (hereinafter referred to as "RuiJing Bio") independently developed the "Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit (Joint Probe Anchoring Polymerization Sequencing Method)" officially received a Class III Medical Device Registration Certificate(Registration No.: 20263401321) issued by the National Medical Products Administration (NMPA). As the first and only NGS-based thyroid cancer molecular detection kit approved in China, this certification fills a critical gap in compliant clinical NGS appli...

浏览次数：43

查看详情>>

发布时间: 2026 - 06 - 22

Efung News | ProteLight Pharma’s World’s First Granulin-Class Antimicrobial Peptide Drug

ProteLight Pharma announced that its independently developed China’s first Class 1 innovative granulin-class antimicrobial peptide drug, Puyike® (Peleganan Spray), received approval for market launch from the National Medical Products Administration (NMPA) on June 17, 2026. The drug is primarily indicated for the treatment of secondary wound infections such as burns and scalds.Peleganan Spray is a First-in-class (FIC) new drug independently developed based on ProteLight Pharma’s Antimicrobial Peptide Drug Design Platform (AMPDDP). The successful approval marks the global debut of the firs...

浏览次数：17

查看详情>>